Article By:
Tony Daltorio
Saturday, January 14, 2023 8:36 AM EDT
Between Covid, the flu, and RSV, investors in over-the-counter consumer pharmaceutical companies might be wondering if now is a logical time to up their holdings in the companies that make cold and flu medicines. Let’s take a look.
There Is Beta In Protalix Stock Due To PRX-102
Isn't that made by Sanofi $SNY?
Protalix BioTherapeutics Pipeline Progress
#Protalix clearly has a lot of potential but there's a limited number of people who will need this drug. So the real question is how much of a dent will they put into #Sanofi's market share. $PLX $SNY
Protalix BioTherapeutics Pipeline Progress
My pleasure. What's more important than how prevalent the disease is, is how much money #Protalix can make on its new drug. It's competitor, #Sanofi ($SNY) makes $1 billion in revenue annually on their drug. Protalix's sounds like a more promising alternative. I'd definitely rate $PLX a buy.